Follow us on social media
Home / Biohacking Academy / Longevity
LongevityEvidence: Preclinical + early human data

Cellular longevity: what the evidence says about NAD+

A no-promises review of what current research documents about NAD+, why its levels change with age, and which questions remain open.

Listen to this articleAudio version
0:00 / 3:15
In this article
Key takeaways
  • NAD+ is a central coenzyme in energy metabolism and a required substrate for sirtuins and PARPs.
  • Tissue NAD+ declines with age in many models, driven in part by increased consumption by the enzyme CD38.
  • Raising NAD+ in humans is achievable; translating that into functional outcomes is still being studied.

Few molecules have moved from biochemistry textbooks to longevity headlines as quickly as nicotinamide adenine dinucleotide, NAD+. The interest is grounded in real biology. The hype, at times, is ahead of the data. This article separates the two.

500+Enzymatic reactions that use NAD(H) as a cofactor
CD38Enzyme linked to age-related NAD+ decline
~60%Rise in blood-cell NAD+ in a human precursor trial

What NAD+ does in the cell

NAD+ has two broad jobs . As a redox cofactor, it shuttles electrons in glycolysis, the TCA cycle and oxidative phosphorylation, which makes it essential for ATP production. As a substrate, it is consumed by signaling enzymes: the sirtuins (deacylases involved in metabolic and stress responses), the PARPs (central to DNA repair) and CD38/CD157 (involved in calcium signaling and immunity).

Why levels fall with age

In multiple animal models and some human tissues, NAD+ levels decline with age. One well-supported driver is increased expression of CD38, an NAD+-consuming enzyme that rises with age and inflammation; in mice, CD38 deficiency preserves NAD+ levels and mitochondrial function . Chronic DNA damage, which keeps PARPs active, adds further demand.

The question is no longer whether NAD+ can be raised. It is whether raising it changes anything that matters.

Precursors vs. NAD+ itself

Research has explored several routes to raise NAD+: precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), direct NAD+, and inhibition of NAD+-consuming enzymes . Each has different uptake routes and tissue distribution, and comparisons between them are still an active area of study.

What human studies show so far

In a randomized, placebo-controlled crossover trial in healthy middle-aged and older adults, six weeks of NR was well tolerated and raised NAD+ in peripheral blood mononuclear cells by roughly 60% . Effects on blood pressure and arterial stiffness were suggestive but not definitive. Across the broader literature, biomarker changes are consistent; functional outcomes such as muscle performance or insulin sensitivity have been mixed.

QuestionStatus of the evidence
Does NAD+ decline with age?Supported in many animal tissues; tissue-dependent in humans
Can it be raised?Yes, in blood and some tissues
Does that improve function?Mixed and still under study
Long-term effects?Largely unknown

Open questions

  • Does NAD+ measured in blood reflect what happens inside muscle, liver or brain?
  • Which tissues benefit most, and which compound reaches them best?
  • How do NAD+-raising strategies interact with exercise, diet and circadian rhythm?

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141.
  2. Rajman L, Chellappa K, Baur JA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–547.
  3. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139.
  4. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.

This article is for educational and research purposes only. Peptogen products are research-grade compounds intended exclusively for laboratory and in-vitro research. They are not for human or animal consumption, diagnostic or therapeutic use, and nothing here constitutes medical advice or dosing guidance.

NAD+ 750 mg vial
Related research compound

NAD+ 750 mg

$150 USD